Fitbit Awaiting Regulatory OKs on ECG App for Its Most Advanced Health Smartwatch
Fitbit is taking preorders for two smartwatches and a tracker slated for late September availability, including the Sense ($329), billing it as its most advanced health smartwatch. The Sense has an electrodermal activity sensor for stress management, an on-wrist-based skin…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
temperature sensor and an electrocardiogram (ECG) app. When used with Fitbit Premium ($9.99 monthly), the watch can help track heart rate variability, breathing rate, and oxygen saturation using the company’s Health Metrics dashboard, said the company Tuesday. Pending regulatory approvals show the challenging route to digital health solutions for consumer tech companies. The ECG app, not intended for use by people under 22, will be available in the U.S., based on FDA clearance. It hasn’t received a CE mark and “will not be marketed, put into service or made available in the European Union until it receives regulatory approval,” Fitbit said. The Sense’s EDA sensor measures electrodermal activity responses; users place their palm over the watch face to detect small electrical changes in the sweat level of the skin. A stress management score calculates how the body is responding to stress based on heart rate, sleep and activity data, it said. Sense is Fitbit’s first device with an ECG app to assess heart rhythm for signs of atrial fibrillation. Results from a COVID-19 study of 100,000 Fitbit users suggested that changes in some metrics included in the new dashboard in the company’s Premium subscription service -- breathing rate, resting heart rate and heart rate variability -- can be detected by Fitbit devices simultaneously with the onset of COVID-19 symptoms, “and in some cases even before,” it said. Wearables “may be able to play an important role in the early detection of infectious diseases by acting as an early warning system for our bodies, which is critical to slowing the spread of COVID-19 and to better understanding disease progression,” said Chief Technology Officer Eric Friedman. “Our algorithm can detect nearly 50 percent of COVID-19 cases a day before the onset of symptoms with 70 percent specificity." The research could help detect other diseases in the future, he said. Fitbit also unveiled the Versa 3 smartwatch ($229) with GPS and Google Assistant. Also coming is the Inspire 2 tracker ($99) with a brighter screen, heart-rate tracking and 10-day battery life.